Cold Sore Market
With Lipivir®, Devirex possesses the only preventive solution against cold sores
The Market
- In the examined markets, 33% of the population have at least 1 herpes outbreak/year*
- 10% of the population have between 3-20 outbreaks*
Positioning of lipivir®
- Lipivir® in the prevention and personal care segment
- High accessibility as it is not a pharmaceutical product. "Direct to customer" possible without constraints (multi-channel)
- Vegan and cruelty-free product
Unique selling points
- Preventive use averts outbreaks of cold sores (HSV-1)**
- Preventive use averts long acute treatments*** (7-8 days)
- 9 out of 10 outbreaks are prevented
- Lipivir® promotes well-being and strengthens the confidence and self-assurance of those affected
* Detailed analyses are available and were carried out by Devirex in 2017 with renowned research institutes
** Herpes simplex virus, HSV-1
*** Clinical study at the University Hospital of Zurich (88% effectiveness)
Devirex AG
Rothusstrasse 7
CH-6331 Hünenberg
+41 41 758 00 00
info@devirex.ch